Skip to main content

Oric Pharmaceuticals, Inc.

corporate_fare Company Profile

Oric Pharmaceuticals, Inc.

ORIC·NASDAQ·Life Sciences·CIK 0001796280

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing therapeutic resistance in cancer. The company's research and development team is developing clinical therapies to counter resistance mechanisms in cancer, specifically in hormone-dependent cancers, precision oncology, and key tumor dependencies. ORIC Pharmaceuticals' clinical-stage product candidates include Rinzimetostat (formerly ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit. The company licensed the development and commercialization rights for Rinzimetostat from Mirati Therapeutics, Inc. under a license agreement. An Investigational New Drug application (IND) for Rinzimetostat was filed and cleared with the Food and Drug Administration (FDA) in the fourth quarter of 2021. ORIC Pharmaceuticals completed a Phase 1b trial of Rinzimetostat as a single-agent in patients with advanced prostate cancer, reporting initial Phase 1b data in January 2024. In July 2024, the company announced that in the first half of 2024, it initiated dosing of Rinzimetostat in combination with apalutamide and in combination with darolutamide, as part of the ongoing Phase 1b trial in patients with metastatic castration resistant prostate cancer (mCRPC).

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for ORIC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 8/10, with 12 rated 8 or above. Recent SEC coverage for ORIC spans 10-Q, 8-K, DEF 14A, 424B5.

Recent high-impact activity:

  • ORIC 10-Q: $345M Cash to 2H 2028, R&D Up 51%, New Insider Selling Plans
  • ORIC Q3: $345M Cash to 2H 2028, Phase 3 Started in Prostate Cancer
  • ORIC Posts $345M Cash Runway to 2028 as First Phase 3 Rinzimetostat Trial Begins
  • ORIC's Enozertinib Hits 84% ORR, Sets Phase 3 Redwood-1 for 1H 2027
  • Enozertinib Hits 84% ORR in 1L EGFR Atypical NSCLC; Phase 3 Set for 1H 2027

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$129.47M
Diluted EPS
-$1.47
Op. Cash Flow
-$110.97M
Free Cash Flow
-$111.68M
Operating Income
-$143M
Cash & Equivalents
$45.67M
Debt / Equity
0.00×
Shares Outstanding
98.53M sh
Source: 10-K · filed 2026-02-23 · accession 0001193125-26-064005

Short Interest & Short Volume

4.80 days to cover

FINRA reported short interest of 10,730,120 shares in ORIC as of the October 30, 2026 settlement, a 30.4% decrease from the prior period — about 4.8 days to cover at its recent average daily volume. On November 20, 2026, 32.7% of ORIC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)10,730,120 shares as of October 30, 2026
Change vs prior period▼ 30.4%
Days to cover4.80 at avg daily volume of 2,236,630
Daily short volume (FINRA facilities)32.7% of 437,910 shares on November 20, 2026
5-day average short volume48.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with O →
$7.37 +0.14% today
52-week range · as of 2026-11-16 $7.23 – $14.68
Market cap
$764.94M
Volume
1.5M (0.8× avg)
3-mo avg 1.8M
Live data · 2026-11-22 05:21 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ORIC - Latest Insights

ORIC
Nov 16, 2026, 4:20 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $7.37 info
Change: -$0.150 (-2%) info
Market Cap: $764.937M info
ORIC
Nov 16, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $7.37 info
Change: -$0.150 (-2%) info
Market Cap: $764.937M info
ORIC
Nov 16, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $7.37 info
Change: -$0.150 (-2%) info
Market Cap: $764.937M info
ORIC
Oct 23, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.32
Real-time Price: $7.37 info
Change: -$5.95 (-45%) info
Market Cap: $764.937M info
ORIC
Oct 23, 2026, 3:15 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $13.85
Real-time Price: $7.37 info
Change: -$6.48 (-47%) info
Market Cap: $764.937M info
ORIC
Aug 03, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $10.58
Real-time Price: $7.37 info
Change: -$3.21 (-30%) info
Market Cap: $764.937M info
ORIC
Aug 03, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.60
Real-time Price: $7.37 info
Change: -$3.23 (-30%) info
Market Cap: $764.937M info
ORIC
Jul 14, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.85
Real-time Price: $7.37 info
Change: -$3.48 (-32%) info
Market Cap: $764.937M info
ORIC
Jun 22, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.93
Real-time Price: $7.37 info
Change: -$1.56 (-17%) info
Market Cap: $764.937M info
ORIC
May 04, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $9.53
Real-time Price: $7.37 info
Change: -$2.16 (-23%) info
Market Cap: $764.937M info
ORIC
May 04, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.53
Real-time Price: $7.37 info
Change: -$2.16 (-23%) info
Market Cap: $764.937M info
ORIC
May 04, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $9.53
Real-time Price: $7.37 info
Change: -$2.16 (-23%) info
Market Cap: $764.937M info
ORIC
Apr 28, 2026, 4:03 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $9.72
Real-time Price: $7.37 info
Change: -$2.35 (-24%) info
Market Cap: $764.937M info
ORIC
Mar 31, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.70
Real-time Price: $7.37 info
Change: -$1.33 (-15%) info
Market Cap: $764.937M info
ORIC
Feb 23, 2026, 5:06 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.71
Real-time Price: $7.37 info
Change: -$4.34 (-37%) info
Market Cap: $764.937M info
ORIC
Feb 23, 2026, 5:02 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $11.71
Real-time Price: $7.37 info
Change: -$4.34 (-37%) info
Market Cap: $764.937M info
ORIC
Feb 23, 2026, 4:15 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $11.71
Real-time Price: $7.37 info
Change: -$4.34 (-37%) info
Market Cap: $764.937M info
ORIC
Feb 23, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.71
Real-time Price: $7.37 info
Change: -$4.34 (-37%) info
Market Cap: $764.937M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets